S&P 500   3,379.16 (+1.31%)
DOW   27,923.76 (+1.72%)
QQQ   279.71 (+1.36%)
AAPL   116.32 (+1.95%)
MSFT   210.89 (+1.75%)
FB   263.16 (+0.52%)
GOOGL   1,476.06 (+0.68%)
AMZN   3,195.02 (+1.59%)
TSLA   428.25 (+2.19%)
NVDA   541.55 (+2.37%)
BABA   291.15 (+5.13%)
CGC   14.46 (-0.28%)
GE   6.26 (+2.29%)
MU   47.90 (-5.54%)
AMD   81.82 (+0.06%)
T   28.57 (+0.95%)
F   6.68 (+1.21%)
ACB   4.71 (+0.64%)
GILD   62.89 (+1.27%)
NFLX   499.57 (+1.23%)
DIS   124.86 (-0.43%)
BA   168.69 (+3.11%)
BAC   24.21 (+1.85%)
S&P 500   3,379.16 (+1.31%)
DOW   27,923.76 (+1.72%)
QQQ   279.71 (+1.36%)
AAPL   116.32 (+1.95%)
MSFT   210.89 (+1.75%)
FB   263.16 (+0.52%)
GOOGL   1,476.06 (+0.68%)
AMZN   3,195.02 (+1.59%)
TSLA   428.25 (+2.19%)
NVDA   541.55 (+2.37%)
BABA   291.15 (+5.13%)
CGC   14.46 (-0.28%)
GE   6.26 (+2.29%)
MU   47.90 (-5.54%)
AMD   81.82 (+0.06%)
T   28.57 (+0.95%)
F   6.68 (+1.21%)
ACB   4.71 (+0.64%)
GILD   62.89 (+1.27%)
NFLX   499.57 (+1.23%)
DIS   124.86 (-0.43%)
BA   168.69 (+3.11%)
BAC   24.21 (+1.85%)
S&P 500   3,379.16 (+1.31%)
DOW   27,923.76 (+1.72%)
QQQ   279.71 (+1.36%)
AAPL   116.32 (+1.95%)
MSFT   210.89 (+1.75%)
FB   263.16 (+0.52%)
GOOGL   1,476.06 (+0.68%)
AMZN   3,195.02 (+1.59%)
TSLA   428.25 (+2.19%)
NVDA   541.55 (+2.37%)
BABA   291.15 (+5.13%)
CGC   14.46 (-0.28%)
GE   6.26 (+2.29%)
MU   47.90 (-5.54%)
AMD   81.82 (+0.06%)
T   28.57 (+0.95%)
F   6.68 (+1.21%)
ACB   4.71 (+0.64%)
GILD   62.89 (+1.27%)
NFLX   499.57 (+1.23%)
DIS   124.86 (-0.43%)
BA   168.69 (+3.11%)
BAC   24.21 (+1.85%)
S&P 500   3,379.16 (+1.31%)
DOW   27,923.76 (+1.72%)
QQQ   279.71 (+1.36%)
AAPL   116.32 (+1.95%)
MSFT   210.89 (+1.75%)
FB   263.16 (+0.52%)
GOOGL   1,476.06 (+0.68%)
AMZN   3,195.02 (+1.59%)
TSLA   428.25 (+2.19%)
NVDA   541.55 (+2.37%)
BABA   291.15 (+5.13%)
CGC   14.46 (-0.28%)
GE   6.26 (+2.29%)
MU   47.90 (-5.54%)
AMD   81.82 (+0.06%)
T   28.57 (+0.95%)
F   6.68 (+1.21%)
ACB   4.71 (+0.64%)
GILD   62.89 (+1.27%)
NFLX   499.57 (+1.23%)
DIS   124.86 (-0.43%)
BA   168.69 (+3.11%)
BAC   24.21 (+1.85%)
Log in
ASX:OCC

Orthocell Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.39
MA: A$0.39▼
A$0.39
52-Week Range N/A
Volume669,530 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and related technologies for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and Poland. The company's principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, an autologous tenocyte implantation for chronic treatment resistant tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. Orthocell Limited was founded in 2006 and is based in Murdoch, Australia.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 1.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.32 out of 5 stars


Industry, Sector and Symbol

Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolASX:OCC
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.orthocell.com.au
Phone61 8 9360 2888

Debt

Debt-to-Equity Ratio2.40
Current Ratio11.18
Quick Ratio11.12

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$719,523.00
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow3.41
Book ValueA$0.11 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive OCC News and Ratings via Email

Sign-up to receive the latest news and ratings for OCC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Orthocell (ASX:OCC) Frequently Asked Questions

Who are some of Orthocell's key competitors?

Some companies that are related to Orthocell include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Acrux (ACR), Actinogen Medical (ACW), Adalta (1AD), Admedus (AHZ), Almirall (LBTSF), Amarantus Bioscience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR), Antibe Therapeutics (VBIZF), Aortech International (RUA), Apotheca Biosciences (CBDC) and Arno Therapeutics (ARNI).
View all competitors.

What other stocks do shareholders of Orthocell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthocell investors own include Plug Power (PLUG), VIRALYTICS Ltd/S (VRACY) and GP Strategies (GPX).

Who are Orthocell's key executives?

Orthocell's management team includes the following people:
  • Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D., Exec. Chairman (Age 49)
  • Mr. Paul Anderson, CEO, MD & Exec. Director (Age 53)
  • Ms. Nicole Telford, Chief Financial Officer
  • Prof. Ming Hao Zheng, Chief Scientific Officer and Member of Medical & Scientific Advisory Board
  • Monique Cannon, Regulatory Affairs & Compliance Mang.

What is Orthocell's stock symbol?

Orthocell trades on the ASX under the ticker symbol "OCC."

How big of a company is Orthocell?

Orthocell has a market capitalization of $0.00 and generates $719,523.00 in revenue each year.

What is Orthocell's official website?

The official website for Orthocell is www.orthocell.com.au.

How can I contact Orthocell?

The company can be reached via phone at 61 8 9360 2888.

This page was last updated on 9/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.